Navigation Links
UCB's Kremers Urban Pharmaceuticals Inc. receives FDA approval for extended release methylphenidate hydrochloride

BRUSSELS and PRINCETON, N.J., July 10, 2013 /PRNewswire/ -- - regulated information - UCB announced today that Kremers Urban Pharmaceuticals Inc. (KU), its U.S. subsidiary focused on specialty generics, received approval from the U.S. Food and Drug Administration (FDA) for 18mg and 27mg extended release methylphenidate hydrochloride product, for which Concerta® is the reference listed drug product. KU has begun launch operations and supplying the US-market with the product. KU also received tentative approval for the 36mg and 54mg. KU will be eligible for final approval after exclusivity expiration in September 2013.

KU's extended release methylphenidate hydrochloride product is bioequivalent to Concerta QD® marketed by ALZA Corporation (a unit of Johnson & Johnson). Each tablet is designed to be effective for 12-hours.

In September 2011, KU announced that it has reached a settlement dismissing all pending litigation arising from its Abbreviated New Drug Application (ANDA) to market an extended release methylphenidate hydrochloride product. The settlement allows Kremers Urban to commercially launch its methylphenidate ANDA product under the existing ALZA Corporation patents.

The launch of KU's new generic product was already considered in UCB's 2013 financial guidance.

For further information

Antje Witte, Investor Relations, UCB
T +32 2 559 9414,

Alexandra Deschner, Investor Relations, UCB
T +32 2 559 9683,

France Nivelle, Global Communications, UCB
T +32 2 559 9178,

Laurent Schots, Media Relations, UCB
T +32.2.559.9264,

Kristie Madara, U.S. Corporate Communications, UCB
T +1 770 970-8726,

Notes to the editor

About UCB
UCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).

About Kremers Urban Pharmacuticals Inc. (KU)
KU is the generic subsidiary of UCB in the US. It is a specialty generic pharmaceutical company focused on difficult, "high barrier" to entry generic products. To learn more visit

UCB Forward-Looking Statement
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations,  changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.  UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Moscamed Launches Urban Scale Project Using Oxitec GM Mosquitoes in Battle Against Dengue
2. A Win for Families: Urban Outfitters Halts Prescription Drug Paraphernalia Product Sales
3. Epidemiology: Rheumatoid Arthritis in China - Rapid urbanization presents favorable market potential
4. Cardinal Health, Detroit Medical Center, Henry Ford Health System Announce Unique Collaboration To Promote Urban Renewal
5. Tris Pharmas Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution
6. Breckenridge Announces Dismissal of Various Lawsuits Against Macoven Pharmaceuticals in Return for Macovens Discontinuance of Certain Products
7. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
8. Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
9. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
10. Vanda Pharmaceuticals, Inc. Sued by Investor
11. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Italian ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Marker Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... ... 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over ... More than 3.7 billion people under the age of 50 – or 67% of ... WHO's first global estimates of HSV-1 infection . , "The data shocks us highly!" ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... prided itself for not only fulfilling the needs of advisers and clients but ... affordable price and providing top-tier customer service. However, there's always room for improvement, ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... ... California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at ... They observed that both STEMI and Sepsis conditions present in similar ways and require ...
(Date:11/26/2015)... NV (PRWEB) , ... November 26, 2015 , ... Inevitably ... strategy. Many customers choose to buy during the Black Friday and Cyber Monday ... Shoppers don’t need to search the Internet high and low to find the best ...
Breaking Medicine News(10 mins):